Neoprobe, Devicor sign gamma detection device asset purchase agreement
 

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has signed a definitive asset purchase agreement to sell its neoprobe GDS line of gamma detection device systems to Devicor Medical Products, Inc. for $30 million in cash, plus a contingent value provision for payment to Neoprobe of up to an additional $20 million in royalties.

More...